Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05730205 · ClinicalTrials.gov registry record · Phase 4

Effects of the Contraceptive Implant in Women With Sickle Cell Disease

A Phase 4 study of Sickle Cell Disease, sponsored by University of Pennsylvania.

Recruiting
Registry status
Phase 4
Development phase
22
Enrollment target
1
Study location

NCT05730205: Recruiting Phase 4 study of Sickle Cell Disease, sponsored by University of Pennsylvania.

NCT05730205 is a Phase 4 study of Sickle Cell Disease that is actively recruiting participants, run by University of Pennsylvania. The registered enrollment target is 22 participants, below the 293-participant average among 213 other Sickle Cell Disease trials with a reported enrollment target (92% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05730205, a Phase 4 study of Sickle Cell Disease, is actively recruiting participants, sponsored by University of Pennsylvania.

RECRUITING
Registry status
Phase 4
Development phase
22 participants
Enrollment target
1
Study location

Study Summary

The objective of this study is to measure the acceptability and impact of the progestin implant on frequency of vaso-occlusive crises, quality of life, and hematologic parameters in women with SCD.

Primary Outcome

Self-reported pain crises, discrete pain episodes will be separated by at least 2 weeks

Conditions Studied

Sickle Cell Disease

Interventions

  • DRUG Nexplanon 68 MG Drug Implant

Study Locations (1)

Pennsylvania

  • Penn Medicine University City - Philadelphia

Trial Details

FieldValue
Enrollment Target 22 participants
Start Date 2023-06-08
Est. Completion 2026-06-15
Phase Phase 4
University of Pennsylvania

1,423 total trials

What NCT05730205 shows while recruiting

NCT05730205 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 22 participants, a relatively small participant target, below the 293-participant average among 213 other Sickle Cell Disease trials with a reported enrollment target (92% lower).

The record links to 1 condition, with Sickle Cell Disease appearing as the primary indexed condition, and to 1 intervention - of which Nexplanon 68 MG Drug Implant is the first listed.

NCT05730205 reports a single indexed study location in Pennsylvania.

Frequently Asked Questions

What is clinical trial NCT05730205 about?

NCT05730205 is a clinical study titled "Effects of the Contraceptive Implant in Women With Sickle Cell Disease". The objective of this study is to measure the acceptability and impact of the progestin implant on frequency of vaso-occlusive crises, quality of life, and hematologic parameters in women with SCD.

What is the current status of trial NCT05730205?

This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 22 participants. The study started on 2023-06-08. Estimated completion is 2026-06-15.

What conditions does trial NCT05730205 study?

This clinical trial studies the following conditions: Sickle Cell Disease.

What interventions are being tested in trial NCT05730205?

The interventions under investigation include: Nexplanon 68 MG Drug Implant (DRUG).

Who is sponsoring clinical trial NCT05730205?

This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05730205 being conducted?

This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Sickle Cell Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT05730205's enrollment target sits among peer trials

22 166th of 213 higher than 46 of 213 other Sickle Cell Disease trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Sickle Cell Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02508038 · 22 participants · Phase 1

    Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors

  • NCT03099356 · 22 participants · Phase 2

    Cyclophosphamide and Sirolimus for the Treatment of Metastatic, RAI-refractory, Differentiated Thyroid Cancer

  • NCT03676647 · 22 participants

    Diagnostic DNA Methylation Signature in Diagnosing Thyroid Cancer After Fine-Needle Aspiration in Patients With Thyroid Nodules

  • NCT04569591 · 22 participants · NA

    DDAVP for Pituitary Adenoma

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

More recruiting context for NCT05730205

Source: ClinicalTrials.gov NCT05730205, the US trial registry maintained by the National Library of Medicine. NCT05730205 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.